TRUTAKNA® (atacicept) has been FDA approved for IgAN, click to learn more. FILSPARI® (sparsentan) has also been FDA approved for FSGS and more information is coming soon. Please visit our Patient Navigation tool for support.
As a seasoned member of the Board of Directors for NephCure, Scott Goldstein brings years of experience and strategic planning. Scott's dedication to advancing kidney care drives his commitment to shaping NephCUre's mission and vision. His unwavering commitment to NephCure's mission underscores their pivotal role in driving positive change within the organization and the broader kidney disease community.
Roslyn, NY
NephCure is a registered non-profit (501c3) tax-exempt charitable organization. EIN # 38-3569922.
© Copyright 2024 NephCure, Inc. All rights reserved worldwide. NephCure, and the logo, are federally registered trademarks of NephCure, Inc.
EN 
ES 